<DOC>
	<DOCNO>NCT01783951</DOCNO>
	<brief_summary>The purpose study evaluate antitumor effect safety clinical effectiveness S-1 plus dendritic cell activate Cytokine induce killer treatment ( DC-CIK ) advance gastric cancer .</brief_summary>
	<brief_title>Study S-1 Plus DC-CIK Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Histologically/cytologically confirm recurrent metastatic gastric esophagogastric junctional adenocarcinoma Between 18 80 year old Capable oral intake Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion Karnofsky Performance Status ( KPS ) ≥ 70 % Normal function heart , lung bone marrow Adequate hematological profile： Hemoglobin ≥ 9.0 g/dL Absolute granulocyte count ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Adequate hepatic function Total bilirubin level≤ 3.0 time upper limit normal ( ULN ) Transaminases AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 time ULN Adequate renal function ( normal serum creatinine level ) A life expectancy≥ 2 month Informed consent sign Current enrollment another clinical study investigational agent . Patients participate survey observational study eligible participate study Any radiotherapy surgery within previous 4 week Symptomatic brain metastasis control corticosteroid Bone marrow metastasis Active infection Serious complication Receiving concomitant treatment drug interact S1 . The following drug prohibit may interaction S1 : phenytoin , potassium warfarin , flucytosine , cimetidine folinic acid . Pregnant lactation woman , woman know suspected pregnancy men want let pregnancy Ineligible study discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>S-1</keyword>
	<keyword>DC-CIK</keyword>
</DOC>